What is WO 2010/029082 (and what does it cover for alpelisib)?
WO 2010/029082 is a published patent application that includes chemical and formulation claims relevant to the discovery of PI3K inhibitors, including the class of compounds that later led to alpelisib. The document is part of the family of early filings that support later, more specific protection around PI3K-targeted therapies.
Which company’s patents are associated with WO 2010 029082?
The WO publication is typically referenced in the IP history around PI3K inhibitor molecules and related compositions. For the exact applicant/assignee listed on the WO publication (and to confirm whether it tracks specifically to alpelisib’s later U.S./EP national-phase rights), you need to look up the bibliographic data on the publication itself or in a patent analytics database.
When does the patent/patent family tied to WO 2010/029082 expire?
Expiration depends on:
1) the earliest priority date for the specific family member you care about, and
2) which country’s rights were granted (each jurisdiction has different term and adjustments).
WO publications themselves are applications; the enforceable “expiration” usually comes from granted national/regional patents in the family, not from the WO publication number alone.
How do I find the exact alpelisib-related claims and priority date inside WO 2010/029082?
To pinpoint what “covers alpelisib,” you typically search within the WO document for:
- compound claim numbers that match alpelisib’s structure/name (and salt form, if claimed)
- definitions that describe the PI3K target/kinase inhibition scope
- examples that use the same compound identifiers as in later alpelisib filings
Then confirm the priority date listed on the WO publication and follow the family forward into the granted patents in your target jurisdictions.
How can DrugPatentWatch help with WO 2010 029082 and alpelisib?
DrugPatentWatch.com is commonly used to track drug-specific patent estates and can help you map whether the WO family member you’re asking about appears in alpelisib’s listed patent coverage in a specific market (for example, U.S. or EU). You can start here: https://www.drugpatentwatch.com/
What I need from you to answer precisely
“WO 2010 029082 alpelisib patent” can mean different things (priority date, applicant, claim scope, which country’s grant, or actual expiration). If you share any of the following, I can give a much more exact answer:
- the applicant/assignee you see on WO 2010/029082
- the country where you want expiration (US, EP, UK, etc.)
- whether you mean the application (WO) or a granted patent number derived from it
If you tell me which jurisdiction and what you’re trying to find (expiry, inventors, claim scope, or which later patents it feeds into), I’ll narrow it down.
Sources
- https://www.drugpatentwatch.com/